Coherus Partners Formycon/Bioeq File Ranibizumab With FDA

Company ‘Excited For Potential Approval In 2022’ For Lucentis Biosimilar

Launch planning is underway for the Lucentis biosimilar that Coherus BioScienes has in-licensed in the US from Formycon and Bioeq, the US-based firm has revealed, as the eye-disease biologic was submitted to the US Food and Drug Administration.

Washington, D.C., USA- January 13, 2020: FDA Sign outside their headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA.
Coherus is eyeing ranibizumab and adalimumab • Source: Shutterstock

Coherus BioSciences now has two biosimilars pending before the US Food and Drug Administration, after Formycon/Bioeq submitted to the agency their biosimilar Lucentis (ranibizumab) candidate for which Coherus holds US commercialization rights.

“Our next expected biosimilar launch is CHS-201, our Lucentis biosimilar candidate,” confirmed company chairman, president and CEO Denny Lanfear, speaking...

More from Biosimilars

More from Products